Read up on our latest news

Each year around the world, 500,000 fetal deaths occur due to preeclampsia, a condition that causes high blood pressure, endangering the mother as well. Previously, doctors had no way of identifying high-risk moms before they showed symptoms, but a new test called Encompass changes that.

Part of the maternal health expansion also included a partnership with predictive and preventative care platform Mirvie to offer a personalized blood test that screens for preeclampsia risks and builds a preventative action plan based on the results.

“We found that using the USPSTF guidelines identified 89% of participants as being at either moderate or high risk for PE,” said lead author Thomas McElrath, MD, PhD, vice president of clinical development at Mirvie and a maternal-fetal medicine specialist at Mass General Brigham. “With the vast majority of the population being labeled as ‘at risk,’ it is unclear if the USPSTF guidelines are serving their intended use of helping clinicians identify patients at most need of additional care.”2

A study published in JAMA Network Open has raised questions about the clinical utility of the U.S. Preventive Services Task Force (USPSTF) guidelines for assessing preeclampsia risk and recommending aspirin prophylaxis (AP) as a preventative treatment. The researchers found that while high-risk factors are valuable in identifying individuals at greater risk of preeclampsia, moderate risk factors lack predictive power, resulting in ineffective and overly broad preventive care strategies.

Maneesh Jain is the Co-Founder and CEO of Mirvie, a company pioneering a new frontier in prenatal care. Its goal is to predict pregnancy complications before they happen using RNA and machine learning.

Mirvie has an astonishing platform that promises to predict pregnancy complications months before they occur, even among those with no apparent risk factors—all with a simple blood test.

Expert guidelines that clinicians across the country use to assess the risk of preeclampsia in pregnant women may be ineffective. The recommendations designed by the U.S. Preventive Services Task Force do not accurately predict risk of developing the condition and lead to nonspecific treatment guidance for the majority of patients, researchers found in a study published Thursday in JAMA Network Open.

Only a tenth of pregnant women assessed as at being moderate risk went on to develop the condition

New research reveals that existing USPSTF guidelines may overgeneralize preeclampsia risk, highlighting the need for biologically based, personalized screening methods to improve maternal outcomes.

The Encompass blood test, developed by Mirvie, provides a tailored action plan that includes a responsive virtual assistant and individualized support to give expectant women and their providers the tools to reduce preeclampsia risks.